Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Novel bioactive natural products presented at the Medicinal Chemistry Symposium

Dec. 11, 2006

Study provides clues on the hypoglycemic action of novel KATP channel modulator

Dec. 11, 2006

Promising preclinical results reported on Seikagaku's novel cathepsin K inhibitor

Dec. 11, 2006

Phase III program under way for oral contraceptive NOMAC/E2

Dec. 7, 2006

Amgen responds to reports on use and safety of Epogen and Aranesp

Dec. 7, 2006

Novel treatment options for obesity reported in recent Novo Nordisk and Takeda patents

Dec. 7, 2006

Recent patents describe new treatment options for endocrine-related disorders

Dec. 7, 2006

FM-VP4 is dose responsive with clinically significant reduction in LDL-cholesterol

Dec. 7, 2006

Pharmacological profile of novel ACAT inhibitor reported by Kyoto

Dec. 7, 2006

Merck & Co. announces trademark Janumet

Dec. 5, 2006

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 15, 2026.
ASGCT 2026: Directed evolution in gene therapy
BioWorld
Directed evolution has become a central pillar in gene therapy. This engineering strategy enables the generation of more efficient variants of genetic editors and...
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...
Fosun secures rights to Aribio’s AR-1001 in potential $4.7B deal
BioWorld
Shanghai Fosun Pharmaceutical (Group) Co. Ltd. is paying $60 million up front for an option to secure exclusive rights to Aribio Co. Ltd.’s oral phase III-stage...
Biogen AD drug shows tau, cognition benefit, despite trial miss
BioWorld
Biogen Inc. has decided to advance diranersen (BIIB-080) into registrational trials for early Alzheimer’s disease, even though the antisense oligonucleotide...